# Losmapimod Safety and Efficacy in COVID-19

> **NCT04511819** · PHASE3 · TERMINATED · sponsor: **Fulcrum Therapeutics** · enrollment: 52 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Losmapimod oral tablet
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04511819
- **Lead sponsor:** Fulcrum Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-28
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Study terminated due to the rapidly evolving environment for the treatment of Covid-19 and ongoing challenges to identify and enroll qualified patients to participate.
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04511819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04511819, "Losmapimod Safety and Efficacy in COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04511819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*